Welcome to our dedicated page for Immunoprecise SEC filings (Ticker: IPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for IPA on Stock Titan provides access to historical regulatory reports for ImmunoPrecise Antibodies Ltd. while it reported under the IPA ticker. These filings include Form 6-K current reports that furnish press releases on topics such as financial results, strategic transactions, scientific milestones, and corporate updates. They offer primary-source insight into how the company described its operations as a biotherapeutics and bio-native AI organization in the pharmaceutical preparation manufacturing space.
Through these documents, readers can follow disclosures about the company’s LENSai™ platform powered by HYFT® technology, its focus on biologics discovery and development, and its shift toward an AI-based drug discovery model. The 6-K filings also transmit information on events like the divestiture of ImmunoPrecise Antibodies (Europe) B.V. to AVS Bio and the later unification of ImmunoPrecise, BioStrand, and Talem under the MindWalk brand with a Nasdaq ticker change from IPA to HYFT.
On Stock Titan, these filings are paired with AI-powered summaries designed to highlight the main points of each report in clear language. Users can quickly see which filings relate to financial performance, which describe scientific or platform advances, and which address corporate actions such as rebranding or strategic realignments. While Forms 10-K, 10-Q, and Form 4 are common reference points for many issuers, ImmunoPrecise, as a foreign private issuer, primarily uses Form 20-F for annual reporting and Form 6-K for interim disclosures, as indicated in its filing headers.
For anyone analyzing the historical IPA symbol, this page offers a structured way to review the company’s regulatory history and to trace its progression toward the MindWalk identity and HYFT ticker, using both the original filings and AI-generated overviews.
MindWalk Holdings Corp. furnished a Form 6-K to share insider trading data reported on Canada’s SEDI system for March 16–20, 2026. Two insiders, Dirk M.H. Van Hyfte and Ingrid M.H. Brands, bought a combined 60,000 common shares in open-market NASDAQ trades, deploying $73,238 at an average price of $1.2178 per share.
Each insider, through vehicles Charmquark EEN and Charmquark TWEE, acquired 30,000 shares, increasing their respective holdings from 1,828,365 to 1,858,365 shares, representing 3.98% of outstanding shares each. The company notes it is exempt from U.S. Section 16 filing requirements and is providing this SEDI-based information voluntarily.
MindWalk Holdings Corp. reported strong top-line growth while remaining loss-making as it pivots to a software-led AI model. Revenue reached $4.2M for the quarter and $11.4M for the nine months ended January 31, 2026, up about 52% and 45% from a year earlier, driven mainly by Canadian B-cell project work.
Quarterly gross margin was 59%, above the company’s historical 48–57% range, with quarterly gross profit of $2.5M. Operating expenses fell sharply versus the prior-year quarter that included a large asset impairment, reducing net loss to $3.9M from $21.5M. For the nine months, net loss was $10.1M, improved from $28.1M.
Cash was $14.1M as of January 31, 2026, and management believes this is sufficient to fund operations for at least one year. Results reflect the shift toward recurring, HYFT- and LensAI-driven revenue, investment in R&D and commercialization, and the divestiture of IPA Europe B.V., which generated $10.2M USD in net proceeds.
MindWalk Holdings Corp. reported strong top-line growth for Q3 fiscal 2026 while remaining loss-making. Revenue reached $4.2 million, up 52% from $2.7 million a year earlier, marking a third consecutive quarter of year-over-year growth. US revenue doubled to $2.6 million, and gross margin for the quarter was 59%, with year-to-date gross margin improving to 58% from 53%.
The company posted a Q3 net loss from continuing operations of $3.9 million, compared with a $22.0 million loss in the prior-year quarter that included a $21.2 million impairment. For the first nine months, revenue rose to $11.4 million from $7.9 million, while the net loss from continuing operations was $11.2 million. Cash and equivalents were $14.2 million as of January 31, 2026, up from $10.8 million at the start of the period, helped by proceeds from the sale of its Europe B.V. business.
Commercially, MindWalk signed its first one-year LensAI™ platform contract with its largest enterprise AI client, creating its first contracted, recurring platform revenue stream. The company also launched its B cell Llama™ nanobody discovery platform and advanced pipeline programs in dengue, GLP-1, and influenza toward further preclinical data.
MindWalk Holdings Corp. introduced B Cell Llama™, a new platform to discover VHH nanobodies, the single‑domain antibody fragments used in bispecific antibodies, multispecific drugs, and CAR‑T cell therapies. The platform extends the company’s existing B Cell Select® technology into llama‑derived antibodies.
A peer‑reviewed study in ACS Biomacromolecules underpins the launch, showing multivalent VHH formats achieved sub‑nanomolar potency, restored activity against resistant variants, and suggested a potential immune‑priming effect. The work also showed that strong binding alone did not guarantee functional activity, supporting MindWalk’s LensAI™ focus on function‑based candidate selection.
The company positions B Cell Llama™ within a broader bio‑native AI strategy that already supports programs in dengue, universal influenza, GLP‑1 and longevity therapeutics, ALK‑1 oncology and rare disease, and other nanobody therapeutics, while holding first rights to commercialize jointly developed intellectual property from the collaboration.
MindWalk Holdings Corp. announced it will report financial results for its third quarter of fiscal year 2026 on March 12, 2026. The company will issue a press release before holding a webcasted earnings conference call at 10:30 AM Eastern Time that includes a management presentation and Q&A.
The live webcast and replay will be accessible through the Events section of MindWalk’s investor relations website. Dial-in numbers are provided for U.S. and Canadian participants, and the company encourages listeners to review its periodic reports and risk factor discussions on SEDAR+ and the SEC’s website.
MindWalk Holdings Corp. filed a Form 6-K highlighting a new application of its proprietary HYFT® technology to detect “functional adjacency” in drug discovery. Functional adjacency means different molecules can deliver the same biological effect even when their sequences look unrelated, which can affect competition, intellectual property, and asset valuation.
Using HYFT in influenza, MindWalk reports finding a conserved biological “signature” that remains stable despite significant genetic changes, supporting its approach to designing broader vaccine targets. The company positions HYFT as part of a broader data and biological reasoning platform intended to help pharmaceutical and biotechnology organizations assess functional competitors, IP exposure, and portfolio risk, and to inform licensing, M&A diligence, and R&D prioritization.